Genelux Corporation
NASDAQ:GNLXBiotechnology
+$0.08 today
- Market cap
- $107.66M
- Beta
- 0.55
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.98
Volume 0.80M
Average 0.19M
GNLX EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Genelux CorporationNASDAQ: GNLX
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.22, compared with -$0.21 a year earlier. Trailing-twelve-month EPS (Diluted) was -$0.88.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 2 analysts of -$0.84 (+2.9%) for the fiscal year ending Dec 2026, a slowdown from the +9.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.22+12.0% QoQ
- Last fiscal yearDec 2025
- -$0.86+9.5% YoY
- LTMMar 2026
- -$0.88+1.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -4.8% | +1.7% | +6.4 pp |
| 1 year | +9.5% | +2.9% | -6.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (0.86) USD
- Year-over-year change
- +9.5%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.86) | +9.5% |
| FY2024 | 2024-12-31 | (0.95) | +18.1% |
| FY2023 | 2023-12-31 | (1.16) | -452.4% |
| FY2022 | 2022-12-31 | (0.21) | +69.6% |
| FY2021 | 2021-12-31 | (0.69) | — |
EPS (Diluted) vs competitors
How GNLX compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +1.1% is the 5th highest of 10, against a peer median of -1.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.22 USD | +99.9% | — | |
| LTM Mar 2026 | -$0.46 USD | +52.9% | — | |
| LTM Mar 2026 | -CHF 0.66 CHF | -26.9% | — | |
| LTM Mar 2026 | -$0.67 USD | -42.8% | — | |
| LTM Mar 2026 | -$0.68 USD | -8.4% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | -$0.88 USD | +1.1% | — |
| LTM Mar 2026 | -$0.98 USD | +20.7% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$1.45 USD | +56.1% | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | -$1.95 USD | -1.0% | — |
| LTM Mar 2026 | -$4.32 USD | — | — | |
| LTM Mar 2026 | -$12.74 USD | -919.7% | — | |
| Peer median (excluding GNLX) | — | -1.0% | — | |
Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 11.07M | 170K | 8K | 8K |
| Cost of Revenue | 895K | 968K | 1.02M | 903K | 574K |
| Gross Profit | (895K) | 10.1M | (848K) | (895K) | (566K) |
| Gross Margin | — | 91.3% | -498.8% | -11187.5% | -7075.0% |
| Research & Development | 6.32M | 9.08M | 12.77M | 19M | 19.85M |
| Selling, General & Admin | 8.29M | 5M | 11.57M | 12.71M | 13.37M |
| Operating Expenses | 13.72M | 13.11M | 23.32M | 30.8M | 32.65M |
| Depreciation & Amortization | 895K | 968K | 1.02M | 903K | 574K |
| EBITDA | (13.67M) | (1.73M) | (26.46M) | (28.97M) | (31.57M) |
| EBITDA Margin | — | -15.6% | -15562.9% | -362075.0% | -394637.5% |
| Operating Income | (14.61M) | (3.01M) | (24.17M) | (31.7M) | (33.21M) |
| Operating Margin | — | -27.2% | -14214.7% | -396200.0% | -415175.0% |
| Interest Income | 0 | 0 | 244K | 1.46M | 1.07M |
| Interest Expense | 1.82M | 1.41M | 3.97M | 0 | 0 |
| Other Income / Expenses | (1.77M) | (1.09M) | (4.13M) | 1.83M | 1.07M |
| Income Before Tax | (16.38M) | (4.11M) | (28.3M) | (29.87M) | (32.15M) |
| Pre-Tax Margin | — | -37.1% | -16645.3% | -373362.5% | -401812.5% |
| Income Tax Expense | 0 | 1.1M | 0 | 0 | 0 |
| Net Income | (17.8M) | (5.21M) | (28.3M) | (29.87M) | (32.15M) |
| Net Margin | — | -47.0% | -16645.3% | -373362.5% | -401812.5% |
| EPS (Basic) | (0.69) | (0.21) | (1.16) | (0.95) | (0.86) |
| EPS (Diluted) | (0.69) | (0.21) | (1.16) | (0.95) | (0.86) |
| Weighted Avg Shares | 23.62M | 24.55M | 24.43M | 31.45M | 37.18M |
| Weighted Avg Shares (Diluted) | 23.62M | 24.55M | 24.43M | 31.45M | 37.18M |
Genelux Corporation
NASDAQ:GNLX
Intrinsic Alpha fair value
Locked
Current Price
$2.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.